Frontotemporal lobar degeneration

Changed by Frank Gaillard, 18 Aug 2021

Updates to Synonym Attributes

Title was added:
Fronto-temporal dementia (FTD)
Type was set to Synonym.
Content was set to .

Updates to Article Attributes

Body was changed:

Frontotemporal lobar degeneration (FTLD) is the pathological description of a group of neurodegenerative disorders characterised by focal atrophy of the frontal and/or temporal cortices. FTLDThese results in variable clinical manifestationmanifestations collectively known as one of the frontotemporal dementia (FTD) syndromes with behavioural and language variants, which in turn overlap with some related motor degenerative conditions syndromes.

Terminology

The conditions grouped under this term vary from publication to publication, depending on whether clinical, pathological or genetic factors are used in the classification and when they were published.

More recent publications, due to the recognition that the type of proteinaceous accumulation correlates with clinical manifestations of FTLDs, has lead to the inclusion of motor variants whichthat encompass amyotrophic lateral sclerosis (ALS), corticobasal degeneration and progressive supranuclear palsy (PSP) 7,8

Terms to use with care

The term frontotemporal dementia (FTD) should be used to denote the clinical syndrome caused by FTLD and should then be followed by the phenotypic variant (behavioural, language, etc). 

Older terms, such as Pick disease should probably be avoided especially when discussing the clinical presentation. Rather it should be reserved for the pathological entity characterised by Pick bodies (a form of tauopathy). 

Epidemiology

The majority of cases are sporadic, however, 20-40% may relate to an autosomal gene. Typically FTLDs occurs in younger patients than Alzheimer disease, usually with onset between 40 to 60 years of age (60%) and 10% being diagnosed <45 years old. Prevalence is estimated at between 1-26 cases per 100,000 population 10

Given the difficulty in clearly defining this group, the incidence is similarly fuzzy, however, it is thought to be the fourth most common cause of progressive dementia (after Alzheimer diseasevascular dementia and Lewy body dementia) accounting for up to 20% of cases.

Clinical presentation

A convenient division based on clinical presentation is into behavioural and language variants. The former demonstrates predominantly frontal lobe changes whereas the latter has a predilection for the temporal lobe (particularly the left), and is further subdivided into a number of clinical distinct entities. As such frontotemporal lobar degeneration can be divided as follows 3--7:

It should be noted that the motor disorders are generally considered separate entities but, however, frequently have overlapping features of FTD 8

Pathology

Over the past decade or two, it has become apparent that FTLD is an umbrella term for a heterogeneous group of diseasediseases that can be characterised based on the type of glial and neuronal proteinaceous inclusions or underlying genetic mutation 7,8

Proteinaceous inclusions

Three major types of FTLD can be defined histologically/biochemically on the basis of the type of proteinaceous inclusions 8

  1. FTLD-Tau: misfolded tau protein (see tauopathies)
  2. FTLD-TDP: transactive response DNA binding protein 43 (TDP-43)
  3. FTLD-FUS: fused in sarcoma protein (rare)
Genetic mutation

Numerous genetic mutations have been identified that usually correlate with both phenotypic and histological/biochemical variants. 

  • FTLD-tau: MAPT gene (tau)
  • FTLD-TDP: GRN (progranulin), VCP, TARBP (TDP-43) and C9ofr72 genes.

Radiographic features

Although, as the name suggests, the frontal and temporal lobes are predominantly affected, depending on the genetic and clinical phenotype, individuals demonstrate very variable regional atrophy.

As a general rule the following dominant patterns of regional loss are demonstrated 8

  • behavioural variant FTD: bilateral frontal lobes
  • semantic variant of PPA: left temporal lobe
  • non-fluent variant of PPA: left insula and frontal operculum (including Broca's area)
  • FTLD-FUS: bilateral caudate nuclei
  • FTLD-TDP due to GRN mutation: right frontal, lateral temporal and parietal lobes, often markedly asymmetric when comparing hemispheres 9
  • FTLD-TDP due to C9orf72 mutation: bilateral hemispheres (generalized)
  • FTLD-tau: due to MAPT mutation: bilateral temporal lobes

In addition to these features that overlap with amyotrophic lateral sclerosis (ALS)corticobasal degenerationprogressive supranuclear palsy (PSP) may be present 8

History and etymology

Frontotemporal dementia was first described by Arnold Pick (1851–1924), Czech psychiatrist, neurologist and neuropathologist, in 1892 11,12.

  • -<p><strong>Frontotemporal lobar degeneration (FTLD)</strong> is the pathological description of a group of <a href="/articles/neurodegenerative-disease">neurodegenerative disorders</a> characterised by focal atrophy of the frontal and temporal cortices. FTLD results in variable clinical manifestation as one of the <a title="Frontotemporal dementia (FTD)" href="/articles/frontotemporal-dementia-4">frontotemporal dementia (FTD)</a> syndromes with behavioural and language variants, which in turn overlap with some related motor degenerative conditions.</p><h4>Terminology</h4><p>The conditions grouped under this term vary from publication to publication, depending on whether clinical, pathological or genetic factors are used in the classification and when they were published. More recent publications, due to the recognition that the type of proteinaceous accumulation correlates with clinical manifestations of FTLDs, has lead to the inclusion of motor variants which encompass <a href="/articles/amyotrophic-lateral-sclerosis-3">amyotrophic lateral sclerosis (ALS)</a>, <a href="/articles/corticobasal-degeneration">corticobasal degeneration</a> and <a href="/articles/progressive-supranuclear-palsy-1">progressive supranuclear palsy (PSP)</a> <sup>7,8</sup>. </p><h5>Terms to use with care</h5><p>The term <a title="Frontotemporal dementia (FTD)" href="/articles/frontotemporal-dementia-4">frontotemporal dementia (FTD)</a> should be used to denote the clinical syndrome caused by FTLD and should then be followed by the phenotypic variant (behavioural, language, etc). </p><p>Older terms, such as <a href="/articles/pick-disease">Pick disease</a> should probably be avoided especially when discussing the clinical presentation. Rather it should be reserved for the pathological entity characterised by <a href="/articles/pick-bodies">Pick bodies</a> (a form of <a href="/articles/tauopathy">tauopathy</a>). </p><h4>Epidemiology</h4><p>The majority of cases are sporadic, however, 20-40% may relate to an autosomal gene. Typically FTLDs occurs in younger patients than Alzheimer, usually with onset between 40 to 60 years of age.</p><p>Given the difficulty in clearly defining this group, the incidence is similarly fuzzy, however, it is thought to be the fourth most common cause of progressive dementia (after <a href="/articles/alzheimer-disease">Alzheimer disease</a>, <a href="/articles/vascular-dementia">vascular dementia</a> and <a href="/articles/dementia-with-lewy-bodies">Lewy body dementia</a>) accounting for up to 20% of cases.</p><h4>Clinical presentation</h4><p>A convenient division based on clinical presentation is into behavioural and language variants. The former demonstrates predominantly frontal lobe changes whereas the latter has a predilection for the temporal lobe (particularly the left), and is further subdivided into a number of clinical distinct entities. As such frontotemporal lobar degeneration can be divided as follows <sup>3--7</sup>:</p><ul>
  • +<p><strong>Frontotemporal lobar degeneration (FTLD)</strong> is the pathological description of a group of <a href="/articles/neurodegenerative-disease">neurodegenerative disorders</a> characterised by focal atrophy of the frontal and/or temporal cortices. These results in variable clinical manifestations collectively known as <strong>frontotemporal dementia (FTD)</strong> syndromes.</p><h4>Terminology</h4><p>The conditions grouped under this term vary from publication to publication, depending on whether clinical, pathological or genetic factors are used in the classification and when they were published.</p><p>More recent publications, due to the recognition that the type of proteinaceous accumulation correlates with clinical manifestations of FTLDs, has lead to the inclusion of motor variants that encompass <a href="/articles/amyotrophic-lateral-sclerosis-3">amyotrophic lateral sclerosis (ALS)</a>, <a href="/articles/corticobasal-degeneration">corticobasal degeneration</a> and <a href="/articles/progressive-supranuclear-palsy-1">progressive supranuclear palsy (PSP)</a> <sup>7,8</sup>. </p><h5>Terms to use with care</h5><p>The term <strong>frontotemporal dementia (FTD)</strong> should be used to denote the clinical syndrome caused by FTLD and should then be followed by the phenotypic variant (behavioural, language, etc). </p><p>Older terms, such as <a href="/articles/pick-disease">Pick disease</a> should probably be avoided especially when discussing the clinical presentation. Rather it should be reserved for the pathological entity characterised by <a href="/articles/pick-bodies">Pick bodies</a> (a form of <a href="/articles/tauopathy">tauopathy</a>). </p><h4>Epidemiology</h4><p>The majority of cases are sporadic, however, 20-40% may relate to an autosomal gene. Typically FTLDs occurs in younger patients than <a href="/articles/alzheimer-disease-1">Alzheimer disease</a>, usually with onset between 40 to 60 years of age (60%) and 10% being diagnosed &lt;45 years old. Prevalence is estimated at between 1-26 cases per 100,000 population <sup>10</sup>. </p><p>Given the difficulty in clearly defining this group, the incidence is similarly fuzzy, however, it is thought to be the fourth most common cause of progressive dementia (after <a href="/articles/alzheimer-disease">Alzheimer disease</a>, <a href="/articles/vascular-dementia">vascular dementia</a> and <a href="/articles/dementia-with-lewy-bodies">Lewy body dementia</a>) accounting for up to 20% of cases.</p><h4>Clinical presentation</h4><p>A convenient division based on clinical presentation is into behavioural and language variants. The former demonstrates predominantly frontal lobe changes whereas the latter has a predilection for the temporal lobe (particularly the left), and is further subdivided into a number of clinical distinct entities. As such frontotemporal lobar degeneration can be divided as follows <sup>3--7</sup>:</p><ul>
  • -</ul><p>It should be noted that the motor disorders are generally considered separate entities but, however, frequently have overlapping features of FTD <sup>8</sup>. </p><h4>Pathology</h4><p>Over the past decade or two, it has become apparent that FTLD is an umbrella term for a heterogeneous group of disease that can be characterised based on the type of glial and neuronal proteinaceous inclusions or underlying genetic mutation <sup>7,8</sup>. </p><h5>Proteinaceous inclusions</h5><p>Three major types of FTLD can be defined histologically/biochemically on the basis of the type of proteinaceous inclusions <sup>8</sup>: </p><ol>
  • +</ul><p>It should be noted that the motor disorders are generally considered separate entities but, however, frequently have overlapping features of FTD <sup>8</sup>. </p><h4>Pathology</h4><p>Over the past decade or two, it has become apparent that FTLD is an umbrella term for a heterogeneous group of diseases that can be characterised based on the type of glial and neuronal proteinaceous inclusions or underlying genetic mutation <sup>7,8</sup>. </p><h5>Proteinaceous inclusions</h5><p>Three major types of FTLD can be defined histologically/biochemically on the basis of the type of proteinaceous inclusions <sup>8</sup>: </p><ol>
  • -</ul><p>In addition to these features that overlap with <a href="/articles/amyotrophic-lateral-sclerosis-3">amyotrophic lateral sclerosis (ALS)</a>, <a href="/articles/corticobasal-degeneration">corticobasal degeneration</a>, <a href="/articles/progressive-supranuclear-palsy-1">progressive supranuclear palsy (PSP)</a> may be present <sup>8</sup>. </p>
  • +</ul><p>In addition to these features that overlap with <a href="/articles/amyotrophic-lateral-sclerosis-3">amyotrophic lateral sclerosis (ALS)</a>, <a href="/articles/corticobasal-degeneration">corticobasal degeneration</a>, <a href="/articles/progressive-supranuclear-palsy-1">progressive supranuclear palsy (PSP)</a> may be present <sup>8</sup>. </p><h4>History and etymology</h4><p>Frontotemporal dementia was first described by <strong>Arnold Pick</strong> (1851–1924), Czech psychiatrist, neurologist and neuropathologist, in 1892 <sup>11,12</sup>.</p>

References changed:

  • 9. Whitwell JL, Josephs KA. Recent advances in the imaging of frontotemporal dementia. (2012) Current neurology and neuroscience reports. 12 (6): 715-23. <a href="https://doi.org/10.1007/s11910-012-0317-0">doi:10.1007/s11910-012-0317-0</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/23015371">Pubmed</a> <span class="ref_v4"></span>
  • 10. Bang J, Spina S, Miller BL. Frontotemporal dementia. (2015) Lancet (London, England). 386 (10004): 1672-82. <a href="https://doi.org/10.1016/S0140-6736(15)00461-4">doi:10.1016/S0140-6736(15)00461-4</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/26595641">Pubmed</a> <span class="ref_v4"></span>
  • 11. Mikol J. History of Pick's Disease. Clin Neuropathol. 2020;39(4):152-61. <a href="https://doi.org/10.5414/NP301243">doi:10.5414/NP301243</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/32000890">Pubmed</a>
  • 12. Olney NT, Spina S, Miller BL. Frontotemporal Dementia. (2017) Neurologic clinics. 35 (2): 339-374. <a href="https://doi.org/10.1016/j.ncl.2017.01.008">doi:10.1016/j.ncl.2017.01.008</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28410663">Pubmed</a> <span class="ref_v4"></span>
  • Whitwell JL, Josephs KA. Recent advances in the imaging of frontotemporal dementia. (2012) Current neurology and neuroscience reports. 12 (6): 715-23. <a href="https://doi.org/10.1007/s11910-012-0317-0">doi:10.1007/s11910-012-0317-0</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/23015371">Pubmed</a> <span class="ref_v4"></span>
Images Changes:

Image 6 MRI (T1) ( update )

Caption was changed:
Case 4: language variant

Image 8 MRI (T1) ( create )

Image 9 MRI (T1) ( create )

Caption was added:
Case 7: behavioural variant

Image 10 Nuclear medicine ( create )

Caption was added:
Case 8: bvFTD and ALS

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.